Vernalis (R&D) is a pharmaceutical company engaged in the research, development, and commercialization of pharmaceutical products. It integrates fragment-based approaches, structural biology, biophysics, assay technology, and molecular modelling with medicinal chemistry expertise to enable drug discovery on both established and novel targets. The company aims to serve patients with oncology, neurodegeneration, anti-infectives, and inflammation disorders.